APPLICATIONS PUBLISHED 2 JULY 2003
Published: 1-Dec-2003
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T +43 1521 260 F +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T +43 1521 260 F +43 1 52126 4492
Novel use of short-chained aldehydes and compounds separating formaldehyde
Henkel 1322281*
Polymeric delivery formulations or leuprolide with improved efficiency
Atrix Laboratories 1322286*
Microparticles for the delivery of heterologous nucleic acids
Chiron 1322287*
Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compsns
Epimmune 1322288*
Spray drying process and compsns of fenofibrate
RTP Pharma 1322289*
Vaccine compsns comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight
Jagotec 1322290*
Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight
Jagotec 1322291*
Microparticle compsns and methods for the manufacture thereof
Chiron 1322292*
Modified release formulation
AstraZeneca 1322293*
Stabilisation of solid thyroid drug formulations
Sigmapharm 1322294*
Stabilisation of solid drug formulations
Sigmapharm 1322295*
Colloidal suspension of submicronic particles for carrying hydrophilic active principles (insulin) and method of preparing same
Flamel Technologies 1322296*
Chrono delivery formulations and method of use thereof
Mehta, Atui M 1322297*
Pharmaceutical oxan preparation
Pierre Fabre Medicament 1322298*
Compsn for the transdermal delivery of fentanyl
3M Innovative Properties 1322299*
Inhalation particles incorporating a combination of two or more active ingredients
Orion Corp 1322300*
Combination particles for the treatment of asthma
Orion Corp 1322301*
Taxoid conjugates as antimitotic and antitumour agents
University of North Carolina at Chapel Hill 1322302*
Delivery system for multi-pharmaceutical active materials at various release rates
Penwest Pharmaceuticals 1322303*
Manipulation of oxidative phosphorylation for hypersensitising tumour cells to glycolitic inhibitors
Lampidis, Theodore J; Priebe, Waldemar 1322304*
Use of R-arylpropionic acids for producing medicaments for treating illnesses with a rheumatic nature
PAZ Arzneimittel-Entiwicklungsgesellschaft 1322305*
Use of statins (HMG-CoA reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
Novimmune 1322306*
Methods for treating cell proliferative disorders and viral infections
Sloan-Kettering Institute for Cancer Research 1322307*
Devices and methods for management of inflammation
Durect Corp 1322308*
High affinity small molecule C5A receptor modulators
Neurogen 1322309*
Alpha V integrin receptor antagonists
Merck 1322310*
Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist
Merck 1322311*
Use of medicaments
Glaxo Group 1322312*
Controlled release formulations for oral administration
Ranbaxy Laboratories 1322313*
Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter
Mitokor 1322314*
Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
Daewoong Pharmaceutical 1322315*
Diuretic or sulphonylurea for use in antiviral treatment
Henderson Morley Research and Development 1322316*
Compsns and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compsns comprising unfractionated cellular proteins
University of Connecticut Health Centre 1322317*
Use of probiotic lactic acid bacteria for balancing the skin's immune system
Societe des Produits Nestle 1322318*
Use of IL-8 protein modulators in the treatment of viral infections
SmithKline Beecham 1322319*
Perilipin as a target for regulation of body weight, muscle mass and diabetes
Baylor College of Medicine 1322320*
Use of lipopeptides or lipoproteins for treating lung infections and lung tumours
Gesellschaft fuer Biotechnologische Forschung 1322321*
Compounds and methods for inhibiting alpha-1 beta-1 integrins
Temple University of the Commonwealth System of Higher Education 1322322*
Thionin as an antineoplastic and immunostimulant
Therapro Technologies 1322323*
Methods for treating muscle injuries
Allergan 1322324*
Inhibiting hepatitis C virus processing and replication
Merck 1322325*
Stabilisation of plasmid inheritance in bacteria by preventing multimerisation
Acambis Research 1322327*
Fatty acid synthase inhibitors
SmithKline Beecham 1322331*
Compsns and methods for inhibition of HIV-1 infection
Progenics Pharmaceuticals 1322332*
Compsn for combined use of aromatase inhibitors
Pharmacia Italia 1322333*
Methods of inducing cancer cell death and tumour remission
Daley, George Q 1322334*
Stable solid forms of amino acids and processes for producing same
Sigmapharm 1322335*
Method of increasing testosterone and related steroid concentrations in women
Unimed Pharmaceuticals 1322336*
PEI:DNA vector formulations for in vitro and in vivo gene delivery
Board of Regents, the University of Texas System 1322337*
Compsns and methods of using capsid proteins from flaviviruses and pestiviruses
The Trustees of the University of Pennsylvania 1322338*
